The U.S. Federal Trade Commission (FTC) notified Sanofi-Aventis U.S. LLC, Watson Pharmaceuticals, Inc., and Synthon Holding B.V., alleging that the companies violated the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) by failing to inform antitrust authorities about drug patent agreements involving Sanofi’s insomnia drug Ambien CR. The MMA requires companies to file such agreements with the FTC and U.S. Department of Justice within 10 business days of their execution, or else face a civil penalty of $11,000 per day. The FTC decided not to recommend an enforcement action because the violation did not appear to have harmed consumers or benefitted the companies, and the failure to file did not appear to have been a deliberate effort to evade the requirements of the MMA.